Waldrep T W, Summers K K, Chiliade P A
South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Immunosuppression Clinic, San Antonio, USA.
Pharmacotherapy. 2000 Dec;20(12):1499-507. doi: 10.1592/phco.20.19.1499.34859.
Chronic infection with the hepatitis C virus (HCV) is a major public health threat in the United States and worldwide. By sharing some routes of transmission, persons infected with the human immunodeficiency virus (HIV) are at risk for coinfection with HCV As a result, hepatic cirrhosis, end-stage liver disease, and hepatocellular carcinoma due to chronic infection with HCV are important causes of both morbidity and mortality in coinfected patients. The advent of highly active antiretroviral therapy improved the management of patients with HIV, leading to decreased morbidity and better survival. As patients infected with HIV live longer, their risk of long-term sequelae from chronic HCV increases. Coinfection with HIV may be associated with rapid progression of chronic HCV. In contrast, the effect of HCV on the natural history of HIV is less clear. Data regarding treatment of HCV in HIV-coinfected patients are limited.
丙型肝炎病毒(HCV)慢性感染是美国乃至全球面临的一项重大公共卫生威胁。由于人类免疫缺陷病毒(HIV)感染者与HCV感染者存在一些共同的传播途径,因此他们有感染HCV的风险。因此,HCV慢性感染导致的肝硬化、终末期肝病和肝细胞癌是合并感染患者发病和死亡的重要原因。高效抗逆转录病毒疗法的出现改善了HIV患者的治疗管理,降低了发病率,提高了生存率。随着HIV感染者寿命延长,他们因慢性HCV感染而出现长期后遗症的风险增加。HIV合并感染可能与慢性HCV的快速进展有关。相比之下,HCV对HIV自然病程的影响尚不清楚。关于HIV合并感染患者HCV治疗的数据有限。